In its latest success in getting price concessions from drug makers, the National Institute for Health and Care Excellence (NICE) says it is now backing Perjeta (pertuzumab) to treat a certain form of breast cancer on the National Health Service in England and Wales after vendor Roche offered a confidential discount.
The HTA's decision endorsing the drug's use in combination with Herceptin (trastuzumab) and the chemotherapy docetaxel as an option before...





